super circulating tumor infiltrating lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04357509)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04571892 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2020 | Huazhong University of Science and Technology, Shanghai Oriental Hospital |
| NCT04357509 | Phase 1 | May 31, 2020 | Chinese Academy of Medical Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Shanghai Oriental Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1